This Phase 3 trial tests whether a cell therapy called REACT (rilparencel) can slow kidney decline in 685 adults with type 2 diabetes and chronic kidney disease. Participants receive either two injections of their own kidney cells or sham procedures. The study measures changes in…
Phase 3 • Sponsor: Prokidney • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC